|
The ABL Advisor Deal Tables
SELECTED TRANSACTION DETAILS
Hercules Capital Provides Up to $100MM Credit Facility to Altimmune
|
Lenders/Participants
|
Hercules Capital, Inc. [Lender]
|
|
Structure
|
Credit Facility
|
|
Amount
|
$100.000
Million
|
|
Borrower(s)
|
Altimmune
|
|
Description
|
Up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company’s pemvidutide development plans and financing needs. Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune’s option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.
|
|
Industry
|
Biopharmaceuticals
|
|
Location
|
MD
|
| Related Tags |
Biopharmaceuticals, Hercules Capital
|
ABL Advisor
Deal Tables
2025
|
|
|
|